These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 26560753)

  • 1. Modulation of tumor immunity: a patent evaluation of WO2015026684A1.
    Nocentini G; Cari L; Ronchetti S; Riccardi C
    Expert Opin Ther Pat; 2016; 26(3):417-25. PubMed ID: 26560753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
    Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
    J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rational design of anti-GITR-based combination immunotherapy.
    Zappasodi R; Sirard C; Li Y; Budhu S; Abu-Akeel M; Liu C; Yang X; Zhong H; Newman W; Qi J; Wong P; Schaer D; Koon H; Velcheti V; Hellmann MD; Postow MA; Callahan MK; Wolchok JD; Merghoub T
    Nat Med; 2019 May; 25(5):759-766. PubMed ID: 31036879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale for anti-GITR cancer immunotherapy.
    Knee DA; Hewes B; Brogdon JL
    Eur J Cancer; 2016 Nov; 67():1-10. PubMed ID: 27591414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity.
    Kumar P; Bhattacharya P; Prabhakar BS
    J Autoimmun; 2018 Dec; 95():77-99. PubMed ID: 30174217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-glucocorticoid-induced Tumor Necrosis Factor-Related Protein (GITR) Therapy Overcomes Radiation-Induced Treg Immunosuppression and Drives Abscopal Effects.
    Schoenhals JE; Cushman TR; Barsoumian HB; Li A; Cadena AP; Niknam S; Younes AI; Caetano MDS; Cortez MA; Welsh JW
    Front Immunol; 2018; 9():2170. PubMed ID: 30294332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of MK-4166, a Clinical Agonistic Antibody That Targets Human GITR and Inhibits the Generation and Suppressive Effects of T Regulatory Cells.
    Sukumar S; Wilson DC; Yu Y; Wong J; Naravula S; Ermakov G; Riener R; Bhagwat B; Necheva AS; Grein J; Churakova T; Mangadu R; Georgiev P; Manfra D; Pinheiro EM; Sriram V; Bailey WJ; Herzyk D; McClanahan TK; Willingham A; Beebe AM; Sadekova S
    Cancer Res; 2017 Aug; 77(16):4378-4388. PubMed ID: 28611044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucocorticoid-induced TNFR-related gene (GITR) as a therapeutic target for immunotherapy.
    Riccardi C; Ronchetti S; Nocentini G
    Expert Opin Ther Targets; 2018 Sep; 22(9):783-797. PubMed ID: 30107134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist.
    Leyland R; Watkins A; Mulgrew KA; Holoweckyj N; Bamber L; Tigue NJ; Offer E; Andrews J; Yan L; Mullins S; Oberst MD; Coates Ulrichsen J; Leinster DA; McGlinchey K; Young L; Morrow M; Hammond SA; Mallinder P; Herath A; Leow CC; Wilkinson RW; Stewart R
    Clin Cancer Res; 2017 Jul; 23(13):3416-3427. PubMed ID: 28069723
    [No Abstract]   [Full Text] [Related]  

  • 10. PD-1 efficiently inhibits T cell activation even in the presence of co-stimulation through CD27 and GITR.
    Mizuno R; Maruhashi T; Sugiura D; Shimizu K; Watada M; Okazaki IM; Okazaki T
    Biochem Biophys Res Commun; 2019 Apr; 511(3):491-497. PubMed ID: 30771904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GITR ligand fusion protein agonist enhances the tumor antigen-specific CD8 T-cell response and leads to long-lasting memory.
    Durham NM; Holoweckyj N; MacGill RS; McGlinchey K; Leow CC; Robbins SH
    J Immunother Cancer; 2017; 5():47. PubMed ID: 28649380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual Roles for Regulatory T-cell Depletion and Costimulatory Signaling in Agonistic GITR Targeting for Tumor Immunotherapy.
    Mahne AE; Mauze S; Joyce-Shaikh B; Xia J; Bowman EP; Beebe AM; Cua DJ; Jain R
    Cancer Res; 2017 Mar; 77(5):1108-1118. PubMed ID: 28122327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peritumoral administration of DRibbles-pulsed antigen-presenting cells enhances the antitumor efficacy of anti-GITR and anti-PD-1 antibodies via an antigen presenting independent mechanism.
    Patel JM; Cui Z; Wen ZF; Dinh CT; Hu HM
    J Immunother Cancer; 2019 Nov; 7(1):311. PubMed ID: 31747946
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Wang B; Zhang W; Jankovic V; Golubov J; Poon P; Oswald EM; Gurer C; Wei J; Ramos I; Wu Q; Waite J; Ni M; Adler C; Wei Y; Macdonald L; Rowlands T; Brydges S; Siao J; Poueymirou W; MacDonald D; Yancopoulos GD; Sleeman MA; Murphy AJ; Skokos D
    Sci Immunol; 2018 Nov; 3(29):. PubMed ID: 30389797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy.
    Snell LM; Lin GH; McPherson AJ; Moraes TJ; Watts TH
    Immunol Rev; 2011 Nov; 244(1):197-217. PubMed ID: 22017440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy.
    Shrimali R; Ahmad S; Berrong Z; Okoev G; Matevosyan A; Razavi GSE; Petit R; Gupta S; Mkrtichyan M; Khleif SN
    J Immunother Cancer; 2017 Aug; 5(1):64. PubMed ID: 28807056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination GITR targeting/PD-1 blockade with vaccination drives robust antigen-specific antitumor immunity.
    Villarreal DO; Chin D; Smith MA; Luistro LL; Snyder LA
    Oncotarget; 2017 Jun; 8(24):39117-39130. PubMed ID: 28388572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative systems pharmacology model of GITR-mediated T cell dynamics in tumor microenvironment.
    Ji Y; Madrasi K; Knee DA; Gruenbaum L; Apgar JF; Burke JM; Gomes B
    CPT Pharmacometrics Syst Pharmacol; 2023 Mar; 12(3):413-424. PubMed ID: 36710369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Authentic GITR Signaling Fails To Induce Tumor Regression unless Foxp3+ Regulatory T Cells Are Depleted.
    Kim YH; Shin SM; Choi BK; Oh HS; Kim CH; Lee SJ; Kim KH; Lee DG; Park SH; Kwon BS
    J Immunol; 2015 Nov; 195(10):4721-9. PubMed ID: 26423152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-GITR Antibody Treatment Increases TCR Repertoire Diversity of Regulatory but not Effector T Cells Engaged in the Immune Response Against B16 Melanoma.
    Scirka B; Szurek E; Pietrzak M; Rempala G; Kisielow P; Ignatowicz L; Miazek A
    Arch Immunol Ther Exp (Warsz); 2017 Dec; 65(6):553-564. PubMed ID: 28638937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.